Perspectives from masters in rheumatology and autoimmunity: Can we get closer to a cure for rheumatoid arthritis?

Arthritis and Rheumatology

Volumn 67, Issue 9, 2015, Pages 2283-2291

  Feldmann, Marc ^a   Maini, Ravinder N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANGIOGENESIS; ANTIGEN SPECIFICITY; AUTOIMMUNITY; BODY MASS; COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE DURATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG COMBINATION; DRUG DEVELOPMENT; MOLECULARLY TARGETED THERAPY; RHEUMATOLOGY; TRENDS;

ANGIOGENESIS INHIBITORS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; HUMANS; INTERLEUKIN-17; MOLECULAR TARGETED THERAPY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RHEUMATOLOGY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940105149     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39269     Document Type: Review

References (60)

1. Erhardt CC, Mumford PA, Venables PJ, Maini RN., Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989; 48: 7-13.
2. Caldwell JR, Furst DE., The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum 1991; 21: 1-11.
3. Taniguchi T, Fujii-Kuriyama Y, Muramatsu M., Molecular cloning of human interferon cDNA. Proc Natl Acad Sci U S A 1980; 77: 4003-6.
4. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR., Making antibodies by phage display technology. Annu Rev Immunol 1994; 12: 433-55.
5. Feldmann M, Maini RN., TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9: 1245-50.
6. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al., American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
7. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
8. Smolen JS, Aletaha, D., Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis 2013; 72: 3-6.
9. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT., Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-40.
10. Smolen JS, Lipsky PE, editors. Contemporary targeted therapies in rheumatology. Boca Raton (FL): CRC Press; 2007.
11. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, et al., A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 2011; 38: 846-54.
12. Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al., The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015; 74: 1311-6.
13. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al., Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013; 72: 863-9.
14. Sabin CA., Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med 2013; 11: 251.
15. Pui CH, Robison LL, Look AT., Acute lymphoblastic leukaemia. Lancet 2008; 271: 1030-43.
16. Cheson BD, Leonard JP., Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma [review]. N Engl J Med 2008; 359: 613-26.
17. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al., Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
18. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al., Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1164-70.
19. Gaujoux-Viala C, Nam J, Ramiro S, Landewe R, Buch MH, Smolen JS, et al., Efficacy of conventional synthetic disease-modifying anti-rheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 510-5.
20. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al., Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
21. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al., Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
22. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al., for the 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50: 1412-9.
23. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al., Selective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007; 66: 228-34.
24. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5.
25. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N., Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
26. Afuwape AO, Feldmann M, Paleolog EM., Adenoviral delivery of soluble VEGF receptor-1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther 2003; 10: 1950-60.
27. Sumariwalla PF, Cao Y, Wu HL, Feldmann M, Paleolog EM., The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther 2003; 5: R32-9.
28. Aletaha D, Funovits J, Smolen JS., Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction Ann Rheum Dis 2011; 70: 733-9.
29. Miller MC, Manning HB, Jain A, Troeberg L, Dudhia J, Essex D, et al., Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. Arthritis Rheum 2009; 60: 686-97.
30. Kaneko K, Williams RO, Dransfield DT, Nixon AE, Sandison A, Itoh Y., Selective inhibition of membrane type 1 matrix metalloproteinase abrogates progression of inflammatory arthritis: synergy with TNF blockade. Arthritis Rheumatol 2015. E-pub ahead of print.
31. Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, Chisaka O, et al., Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007; 315: 1006-10.
32. Klein K, Ospelt C, Gay S., Epigenetic contributions in the development of rheumatoid arthritis. Arthritis Res Ther 2012; 14: 227.
33. Andersen-Ranberg K, Hoier-Madsen M, Wiik A, Jeune B, Hegedus L., High prevalence of autoantibodies among Danish centenarians. Clin Exp Immunol 2004; 138: 158-63.
34. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346: 1685-91.
35. Klareskog L, Lundberg K, Malmstrom V., Autoimmunity in rheumatoid arthritis: citrulline immunity and beyond. Adv Immunol 2013; 118: 129-58.
36. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ., PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003; 25: 1106-18.
37. Wegner N, Lundberg K, Kinloch A, Fisher B, Malmstrom V, Feldmann M, et al., Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010; 233: 34-54.
38. Thomas R., Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis. Arthritis Res Ther 2013; 61: 553-60.
39. Benham H, Nel HJ, Law SC, Mehdi AM, Street S, Ramnoruth N, et al., Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med 2015; 7: 1-12.
40. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO., Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008; 205: 2491-7.
41. Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, et al., A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 2014; 66: 1693-704.
42. Chiricozzi A, Krueger JG., IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 2013; 22: 993-1005.
43. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL., Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther 2011; 13: R126.
44. Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, et al., Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis 2012; 71: 1741-8.
45. Goronzy JJ, Weyand CM., Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther 2009; 11: 249.
46. Gwyer Findlay E, Danks L, Madden J, Cavanagh MM, McNamee K, McCann F, et al., OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proc Natl Acad Sci U S A 2014; 111: 2289-94.
47. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-44.
48. Evans EJ, Esnouf RM, Manso-Sancho R, Gilbert RJ, James JR, Yu C, et al., Crystal structure of a soluble CD28-Fab complex. Nat Immunol 2005; 6: 271-9.
49. Zanin-Zhorov A, Ding Y, Kumari S, Attur M, Hippen KL, Brown M, et al., Protein kinase C-θ mediates negative feedback on regulatory T cell function. Science 2010; 328: 372-6.
50. Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, et al., Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 2013; 110: 17945-50.
51. McCann FE, Perocheau DP, Ruspi G, Blazek K, Davies ML, Feldmann M, et al., Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol 2014; 66: 2728-38.
52. Schmidt EM, Davies M, Mistry P, Green P, Giddins G, Feldmann M, et al., Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures. Arthritis Rheum 2013; 65: 2262-73.
53. Isaacs JD, Ferraccioli G., The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011; 70: 4-7.
54. Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, et al., Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 1993; 32: 903-7.
55. Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, et al., Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013; 2: e01202.
56. Mullokandov G, Baccarini A, Ruzo A, Jayaprakash AD, Tung N, Israelow B, et al., High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. Nat Methods 2012; 9: 840-6.
57. Brown BD, Naldini L., Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009; 10: 578-85.
58. Lollo B, Steele F, Gold L., Beyond antibodies: new affinity reagents to unlock the proteome. Proteomics 2014; 14: 638-44.
59. Bendall SC, Simonds EF, Qiu P, Amir ED, Krutzik PO, Finck R, et al., Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011; 332: 687-96.
60. Van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HM, Kerstens PJ, et al., Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011; 70: 1389-94.